Portage Biotech Inc. (NASDAQ:PRTG) Sees Significant Increase in Short Interest

by · The Cerbat Gem

Portage Biotech Inc. (NASDAQ:PRTG – Get Free Report) was the recipient of a significant increase in short interest in September. As of September 30th, there was short interest totalling 17,600 shares, an increase of 87.2% from the September 15th total of 9,400 shares. Based on an average daily volume of 1,760,000 shares, the short-interest ratio is presently 0.0 days. Currently, 4.2% of the company’s stock are short sold.

Portage Biotech Trading Up 1.3 %

Shares of PRTG stock traded up $0.09 on Friday, reaching $6.88. 18,680 shares of the stock were exchanged, compared to its average volume of 594,113. The business’s 50 day moving average price is $4.74 and its 200 day moving average price is $5.37. The company has a market capitalization of $7.22 million, a price-to-earnings ratio of -0.15 and a beta of 1.57. Portage Biotech has a twelve month low of $2.10 and a twelve month high of $53.20.

Portage Biotech (NASDAQ:PRTG – Get Free Report) last issued its earnings results on Thursday, August 15th. The company reported ($24.20) EPS for the quarter. Equities research analysts forecast that Portage Biotech will post -13 earnings per share for the current year.

Institutional Investors Weigh In On Portage Biotech

An institutional investor recently bought a new position in Portage Biotech stock. Sanctuary Advisors LLC bought a new stake in Portage Biotech Inc. (NASDAQ:PRTG – Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 297,728 shares of the company’s stock, valued at approximately $63,000. Sanctuary Advisors LLC owned about 28.36% of Portage Biotech as of its most recent filing with the Securities & Exchange Commission. 13.36% of the stock is owned by hedge funds and other institutional investors.

Portage Biotech Company Profile

(Get Free Report)

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.

See Also